RUA Life Sciences (GB:RUA) has released an update.
RUA Life Sciences reported modest revenue growth and a reduced pre-tax loss for the year ending March 31, 2024, with a strong second half and a strategic pivot towards commercializing its IP in vascular and structural heart products. The company has reduced R&D spending and is now fully funded, focusing on cash generation and a return to profitability, with a healthy year-end cash balance of £3.9 million. Management changes include John McKenna transitioning from an executive role to non-executive director.
For further insights into GB:RUA stock, check out TipRanks’ Stock Analysis page.
